Autolus Insider Compensation
Autolus Director Receives Substantial Equity Awards Including Options and Restricted Stock Units
Key Points
Restricted stock units (RSUs) granted to Autolus insiders vest in a single installment on June 29, 2027, indicating a one-time vesting event rather than multiple milestones.
A share option grant associated with the insider awards was issued on June 29, 2026, suggesting a defined timeline for potential exercise ahead of the RSU vesting.
Some RSUs are described as convertible into ordinary shares at any time, potentially enabling earlier realization of value beyond the standard vesting schedule.
Autolus Therapeutics (AUTL) director Elisabeth Leiderman received 47,500 share options and 31,667 restricted stock units on June 29, 2026, according to Stock Titan. The grants came straight after the company's Annual General Meeting and were part of a board-wide equity award cycle that covered at least six directors.
Each director received an identical package. The options carry a strike price of $1.61 per share — well below the analyst consensus price target of $10.00, according to TipRanks. The awards were filed with the SEC on July 1, 2026.
How the Grants Are Structured and When They Pay Out
The 47,500 options begin vesting on July 29, 2026 — one month after the grant date. They vest monthly over 12 months, giving directors a steady trickle of exercisable equity. The options expire on June 29, 2036, giving a 10-year window to act, according to Stock Titan.
The 31,667 RSUs work differently. They cliff-vest in a single event on June 29, 2027 — exactly one year after the grant. An RSU is a promise to hand over one share once conditions are met. Directors get nothing from the RSUs until that date arrives.
Six Directors Share Identical Awards After AGM Vote
The Compensation Committee granted matching packages to at least six directors: Elisabeth Leiderman, Michael Bonney, Robert Iannone, Ryan Richardson, William D. Young, and Cynthia Butitta. All received 47,500 options and 31,667 RSUs each on the same date, according to Stock Titan.
Combined, the six directors received roughly 285,000 options and 190,000 RSUs. That total represents less than 0.3% of Autolus's shares outstanding, which exceeded 220 million as of the 2025 AGM, according to SEC.gov. The dilution impact is small.
Autolus Hits Commercial Stage With AUCATZYL Launch
The awards arrive at a key moment. Autolus recently became a commercial-stage company after bringing AUCATZYL® to market. AUCATZYL is a CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia. CAR-T therapies re-engineer a patient's own immune cells to fight cancer.
The company reported its first positive gross profit during a recent earnings call, according to TipRanks. Still, an AI sentiment tool rated the stock "Neutral," pointing to high cash burn typical of CAR-T companies. Human analysts rate it a "Buy" with a $10.00 price target.
ADS Structure Gives US Investors Flexible Access to UK Shares
Autolus is a UK company listed on Nasdaq. To make that work, it uses American Depositary Shares, or ADSs. Each ADS equals one ordinary share. Citibank acts as the depositary bank, bridging UK share ownership and US exchange trading, according to SEC.gov.
Directors can convert their ADSs into ordinary shares at any time. That flexibility does not let them skip vesting rules. But it does give them options for how they hold equity once it vests. Separately, Autolus also granted 25,420 options and 87,530 RSUs to 13 new employees on June 24, 2026, under its Inducement Plan, according to GlobeNewswire.
Sentiment
Mostly NegativePublishers
13
Articles
4
Reach
17
